Dr. Yap on the Rationale for the SEASTAR Trial in Advanced Solid Tumors

Timothy Yap, MBBS, PhD, FRCP, medical oncologist, physician-scientist, associate professor, Department for Investigational Cancer Therapeutics, Department of Thoracic/Head and Neck Medical Oncology, medical director, Institute for Applied Cancer Science, associate director, Translational Research, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, discusses the rationale for the ongoing phase 1b/2 SEASTAR trial in advanced solid tumors.

The open-label, multi-arm study will evaluate the efficacy, safety, and pharmacokinetics of the PARP1/2/3 inhibitor rucaparib (Rubraca) in combination with lucitanib or sacituzumab govitecan-hziy (Trodelvy) in patients with advanced or metastatic solid tumors.

Currently, the phase 2 portion of the trial is enrolling patients into 2 arms. The first arm is testing rucaparib with lucitanib, an investigational VEGFR/FGFR TKI, in patients with BRCA wild-type ovarian cancer. 

The second arm is evaluating rucaparib in combination with the antibody-drug conjugate sacituzumab govitecan in patients with metastatic triple-negative breast cancer, advanced/metastatic urothelial carcinoma, or relapsed ovarian cancer.

Rucaparib is currently approved as monotherapy for the treatment of patients with BRCA1/2-mutant metastatic castration-resistant prostate cancer and as maintenance therapy for patients with recurrent ovarian cancer, concludes Yap.